Correlation Between NYSE Composite and Novo Nordisk

Can any of the company-specific risk be diversified away by investing in both NYSE Composite and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NYSE Composite and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NYSE Composite and Novo Nordisk AS, you can compare the effects of market volatilities on NYSE Composite and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NYSE Composite with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of NYSE Composite and Novo Nordisk.

Diversification Opportunities for NYSE Composite and Novo Nordisk

-0.73

Correlation Coefficient

NYSE Composite  Novo Nordisk

Pay attention - limited upside

The 3 months correlation between NYSE and Novo is -0.73. Overlapping area represents the amount of risk that can be diversified away by holding NYSE Composite and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and NYSE Composite is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NYSE Composite are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of NYSE Composite i.e., NYSE Composite and Novo Nordisk go up and down completely randomly.

Pair Corralation between NYSE Composite and Novo Nordisk

Assuming the 90 days trading horizon NYSE Composite is expected to generate 0.23 times more return on investment than Novo Nordisk. However, NYSE Composite is 4.37 times less risky than Novo Nordisk. It trades about 0.36 of its potential returns per unit of risk. Novo Nordisk AS is currently generating about 0.01 per unit of risk. If you would invest  1,924,339  in NYSE Composite on September 5, 2024 and sell it today you would earn a total of  94,521  from holding NYSE Composite or generate 4.91% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

NYSE Composite  vs.  Novo Nordisk AS

Pair Trading with NYSE Composite and Novo Nordisk

The main advantage of trading using opposite NYSE Composite and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NYSE Composite position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.

The idea behind NYSE Composite and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.